EE9900528A - CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks - Google Patents

CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks

Info

Publication number
EE9900528A
EE9900528A EEP199900528A EEP9900528A EE9900528A EE 9900528 A EE9900528 A EE 9900528A EE P199900528 A EEP199900528 A EE P199900528A EE P9900528 A EEP9900528 A EE P9900528A EE 9900528 A EE9900528 A EE 9900528A
Authority
EE
Estonia
Prior art keywords
disruptor
binding
immune responses
graft rejection
adaptive immune
Prior art date
Application number
EEP199900528A
Other languages
English (en)
Estonian (et)
Inventor
D. Kirk Allan
M. Harlan David
W. Thomas David
Kauffman Michael
Burkly Linda
Original Assignee
Biogen, Incorporated
The United States Of America As Represented By The Secretary Of The Navy Chief Ofnaval Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated, The United States Of America As Represented By The Secretary Of The Navy Chief Ofnaval Research filed Critical Biogen, Incorporated
Publication of EE9900528A publication Critical patent/EE9900528A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
EEP199900528A 1997-05-17 1998-05-15 CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks EE9900528A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4679197P 1997-05-17 1997-05-17
US4938997P 1997-06-11 1997-06-11
US8514598P 1998-05-12 1998-05-12
PCT/US1998/010075 WO1998052606A1 (en) 1997-05-17 1998-05-15 Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection

Publications (1)

Publication Number Publication Date
EE9900528A true EE9900528A (et) 2000-06-15

Family

ID=27366975

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900528A EE9900528A (et) 1997-05-17 1998-05-15 CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks

Country Status (20)

Country Link
US (2) US20020119150A1 (zh)
EP (1) EP0980259A1 (zh)
JP (1) JP2002500648A (zh)
KR (1) KR100575069B1 (zh)
CN (1) CN1202864C (zh)
AU (1) AU735592B2 (zh)
BG (1) BG64841B1 (zh)
BR (1) BR9809641A (zh)
CA (1) CA2291156A1 (zh)
EA (1) EA002549B1 (zh)
EE (1) EE9900528A (zh)
HU (1) HUP0003392A3 (zh)
IL (1) IL132882A0 (zh)
IS (1) IS5247A (zh)
NO (1) NO995617L (zh)
NZ (1) NZ500974A (zh)
PL (1) PL192521B1 (zh)
SK (1) SK156099A3 (zh)
TR (1) TR199902817T2 (zh)
WO (1) WO1998052606A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144010B1 (en) * 1999-01-08 2007-04-18 Wisconsin Alumni Research Foundation Prevention of chronic graft rejection by a combination of immunotoxins and costimulation blockers
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
AU784350B2 (en) * 1999-10-22 2006-03-16 Biogen Idec Ma Inc. Use of a CD40:CD154 binding interruptor to treat immunological complications of the eye
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US6797263B2 (en) 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
WO2001095928A2 (en) * 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
EP1179587A1 (de) * 2000-08-09 2002-02-13 Genethor GmbH Verfahren zur Reduzierung von spezifischen Immunreaktionen
MXPA03002262A (es) * 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
AU2004253868B2 (en) * 2003-06-13 2011-06-16 Biogen Ma Inc. Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
WO2007043641A1 (ja) * 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
RU2450830C2 (ru) * 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP1968386A4 (en) * 2005-12-15 2009-07-22 Univ New York State Res Found METHOD FOR TREATING UNDERFUNCTION OF THE IMMUNE SYSTEM BY REGULATING THE CD40 LIGAND EXPRESSION
CA2637917C (en) * 2006-01-27 2015-11-24 Keio University Therapeutic agents for diseases involving choroidal neovascularization
JP5754875B2 (ja) * 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
CL2008000188A1 (es) * 2007-01-23 2008-07-18 Chugai Pharmaceutical Co Ltd Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
EP2305306B1 (en) * 2008-06-05 2016-02-10 National Cancer Center Neuroinvasion inhibitor
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
EP2578231B1 (en) 2010-05-28 2022-10-26 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
KR102656470B1 (ko) 2014-12-10 2024-04-09 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2018217918A2 (en) 2017-05-24 2018-11-29 Als Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201095B (en) * 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
US5068323A (en) * 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
WO1994004188A1 (en) * 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
JPH06298654A (ja) * 1993-04-12 1994-10-25 Sumitomo Electric Ind Ltd 抗原特異的免疫抑制剤
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
PT892643E (pt) * 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
ATE356634T1 (de) * 1997-01-10 2007-04-15 Biogen Idec Inc Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln

Also Published As

Publication number Publication date
KR20010012671A (ko) 2001-02-26
NO995617D0 (no) 1999-11-16
IS5247A (is) 1999-11-12
BG103948A (en) 2000-07-31
PL192521B1 (pl) 2006-11-30
CN1261284A (zh) 2000-07-26
PL336994A1 (en) 2000-07-31
EP0980259A1 (en) 2000-02-23
KR100575069B1 (ko) 2006-05-02
EA002549B1 (ru) 2002-06-27
IL132882A0 (en) 2001-03-19
US20020119150A1 (en) 2002-08-29
AU735592B2 (en) 2001-07-12
AU7494098A (en) 1998-12-11
CN1202864C (zh) 2005-05-25
SK156099A3 (en) 2000-06-12
WO1998052606A1 (en) 1998-11-26
JP2002500648A (ja) 2002-01-08
CA2291156A1 (en) 1998-11-26
US20070244053A1 (en) 2007-10-18
BR9809641A (pt) 2000-07-11
BG64841B1 (bg) 2006-06-30
NO995617L (no) 2000-01-17
HUP0003392A3 (en) 2002-09-30
NZ500974A (en) 2001-06-29
EA199901046A1 (ru) 2000-10-30
HUP0003392A2 (hu) 2001-08-28
TR199902817T2 (xx) 2000-09-21

Similar Documents

Publication Publication Date Title
EE9900528A (et) CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks
HUP1500179A2 (en) The use of human tnf-alpha binding antibodies
AU2002210299A1 (en) Adaptive personal repeater
HUP0100763A3 (en) Antibodies against human cd40
DK0906784T3 (da) Fremgangsmåde til fremstilling af bundne zeolitter
MXPA03001590A (es) Anticuerpos para la il-1beta humana.
GB0027238D0 (en) Adaptive filter
AU1623799A (en) Preparation of zeolite bound by mfi structure type zeolite and use thereof
AU2001280934A1 (en) Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
DE69720211D1 (de) Reihe von sprugfedern
HUP0200912A3 (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual disfunction
DE69801083D1 (de) Adaptives Filter
DE69634466D1 (de) Mehrbenutzerempfang für CDMA
DK1025253T3 (da) Positiv-negativ-selektion ved den homologe rekombination
PL337331A1 (en) Cyanoguanidines as cell proliferation inhibitors
EE9900551A (et) Tsüanoguanidiinid kui rakkude paljunemise inhibiitorid
MXPA02009449A (es) Ligandos dirigidos a la region no del eje del componente no secretor de la pigr y metodos de uso de los mismos.
AU3179999A (en) Methods to treat undesirable immune responses
IT1311568B1 (it) Arnese da cucina per agitare, sbattere e smuovere.
EP1366056A4 (en) PREPARATION OF DEOXYNUCLEOSIDES
AU2003285483A1 (en) Conjugate composition comprising antibodies against cd40 or cd28
AU7942498A (en) Compositions and methods for sedating, anaesthetising and euthanising aquatic organisms
GB9915108D0 (en) Zeolite filter
EP1354601A4 (en) INHIBITORS OF RELEASE OF TRANSPLANT ORGANS
IT1296895B1 (it) Equalizzatore di ritardo di gruppo

Legal Events

Date Code Title Description
HC1A Change of owner name